Repligen Corp RGEN:NASDAQ

Last Price$276.84NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/01/21

Today's Change-9.66(3.37%)
Bid (Size)$269.68 (1)
Ask (Size)$287.00 (1)
Day Low / High$273.79 - 292.00
Volume592.1 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 12/01/2021

 

Repligen Corp ( NASDAQ )

Price: $276.84
Change: -9.66 (3.37%)
Volume: 592.1 K
4:00PM ET 12/01/2021
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $84.50
Change: -1.79 (2.07%)
Volume: 1.2 M
4:00PM ET 12/01/2021
 
 

Novavax Inc ( NASDAQ )

Price: $192.65
Change: -15.98 (7.66%)
Volume: 9.7 K
4:00PM ET 12/01/2021
 
 

Incyte Corp ( NASDAQ )

Price: $64.96
Change: -2.76 (4.08%)
Volume: 3.7 M
4:00PM ET 12/01/2021
 
 

Exact Sciences Corp ( NASDAQ )

Price: $80.28
Change: -5.09 (5.96%)
Volume: 1.9 M
4:00PM ET 12/01/2021
 

Read more news Recent News

Insider Sell: Repligen
7:56AM ET 11/22/2021 MT Newswires

Anthony Hunt, Director, Chief Executive Officer, on November 18, 2021, sold 17,355 shares in Repligen (RGEN) for $4,804,674. Following the Form 4 filing...

Insider Sell: Repligen
7:18AM ET 11/15/2021 MT Newswires

Karen A Dawes, Director, on November 10, 2021, sold 4,783 shares in Repligen (RGEN) for $1,262,355. Following the Form 4 filing with the SEC, Dawes has...

Insider Sell: Repligen
5:53PM ET 11/04/2021 MT Newswires

Karen A Dawes, Director, on November 02, 2021, sold 2,400 shares in Repligen (RGEN) for $729,467. Following the Form 4 filing with the SEC, Dawes has...

Insider Sell: Repligen
5:53PM ET 11/04/2021 MT Newswires

Thomas F Ryan Jr, Director, on November 02, 2021, sold 2,285 shares in Repligen (RGEN) for $676,070. Following the Form 4 filing with the SEC, Ryan has...

View all Commentary and Analysis

Landslide Portfolio Earnings Review (Part 1)
4:22AM ET 11/13/2021 Seeking Alpha

Repligen Corporation (RGEN) CEO Anthony Hunt on Q3 2021 Results - Earnings Call Transcript
3:43PM ET 10/28/2021 Seeking Alpha

The Landslide Portfolio
8:18PM ET 9/14/2021 Seeking Alpha

Don't Expect Much From The Fed At Virtual Jackson Hole
5:31AM ET 8/27/2021 Seeking Alpha

Company Profile

Business DescriptionRepligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA. View company web site for more details
Address41 Seyon Street
Waltham, Massachusetts 02453
Phone+1.781.250.0111
Number of Employees548
Recent SEC Filing11/19/20214
President, Chief Executive Officer & DirectorTony J. Hunt
Senior Vice President-Global Operations & ITJames R. Bylund
Chief Financial OfficerJon K. Snodgres
Senior Vice President-Research & DevelopmentRalf Kuriyel

Company Highlights

Price Open$286.60
Previous Close$276.84
52 Week Range$162.29 - 327.32
Market Capitalization$15.3 B
Shares Outstanding55.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings136.20
Earnings per Share$2.26
Beta vs. S&P 500N/A
Revenue$194.0 M
Net Profit Margin20.06%
Return on Equity7.43%

Analyst Ratings as of 10/13/2021

Buy
8
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset